Semaglutide Contains one mechanism of action: A GLP-1 agonist Decreases appetite, increases production of insulin, and increases satiety Used for patients seeking weight loss, patients suffering from Polycystic Ovarian Syndrome (PCOS), and those with insulin resistance
15 , 30 Similarly, tirzepatide was associated with reductions in weight, fat mass, reduced energy intake, and reduced appetite in a Phase 1 mechanism of action study in patients with type 2 diabetes
Atindra Bhatnagar Address House No.33, Rivera Town, Mata Mandir, Bhopal, Madhya Pradesh, 462003, India Report incorrect details
Clinical trials have demonstrated significant weight loss among those using Semaglutide, sparking interest in its potential as a treatment for obesity independent of diabetes